We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Sends Mixed Signals on Braeburn Opioid MAT
FDA Advisory Committee Sends Mixed Signals on Braeburn Opioid MAT
FDA advisory committee members recommended approval for some versions of Braeburn’s modified-release reformulation of buprenorphine but balked at endorsing higher dosages of the medication, which is indicated for weekly or monthly treatment of opioid abuse.